1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Technology appraisal guidance [TA593] Published date: 14 August 2019

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

  • Evaluation report  
  • Final appraisal determination committee papers PDF 799.53 KB 14 August 2019  
  • Appraisal consultation committee papers PDF 5.98 MB 14 August 2019